TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Bergentoft Pharma Consulting AB
Closing information (x1000 EUR)
Closing information | 2022/12 | 2021/12 | 2020/12 |
Turnover | 185 | 115 | 61 |
Financial expenses | 0 | 0 | 0 |
Earnings before taxes | 114 | 79 | 36 |
EBITDA | 114 | 79 | 36 |
Total assets | 264 | 166 | 104 |
Current assets | 174 | 166 | 104 |
Current liabilities | 69 | 40 | 21 |
Equity capital | 181 | 118 | 75 |
- share capital | 4 | 5 | 5 |
Employees (average) | 1 | 1 | 1 |
Financial ratios
Fiscal year | 2022/12 | 2021/12 | 2020/12 |
Solvency | 68.6% | 71.1% | 72.1% |
Turnover per employee | 185 | 115 | 61 |
Profit as a percentage of turnover | 61.6% | 68.7% | 59.0% |
Return on assets (ROA) | 43.2% | 47.6% | 34.6% |
Current ratio | 252.2% | 415.0% | 495.2% |
Return on equity (ROE) | 63.0% | 66.9% | 48.0% |
Change turnover | 79 | 55 | -36 |
Change turnover % | 75% | 91% | -37% |
Chg. No. of employees | 0 | 0 | 0 |
Chg. No. of employees % | 0% | 0% | 0% |
Total value of public sale
Fiscal year | 2022/12 | 2021/12 | 2020/12 |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.